Navigation Links
Watson Confirms NIASPAN(R) Patent Challenge
Date:3/19/2012

PARSIPPANY, N.J., March 19, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc. – Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Niacin Extended-release Tablets, 500 mg and 1000 mg. Watson's ANDA products are generic versions of Abbott Laboratories' NIASPAN®.

Abbott Laboratories and Abbott Respiratory LLC filed suit against Watson on March 16, 2012, in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its ANDA products prior to the expiration of U.S. Patent Nos. 6,080,428 and 6,469,035.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

For the twelve months ending January 31, 2012, NIASPAN® had total U.S. sales of approximately $1.2 billion according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are f
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , Oct. 24, 2014 ... "Dental Equipment Market Current Trends, Opportunities - Global ... In this report, the global dental equipment ... geography. The dental systems and equipment market is expected ... equipment market during the forecast period (2014 to 2019). ...
(Date:10/25/2014)... , Oct. 24, 2014  America,s future engineers ... robotic competition at the  Medical Design and Manufacturing ... 29-30 th at the Minneapolis ... local student built robots from the "For Inspiration ... FIRST students and mentors will offer information to ...
(Date:10/25/2014)... , October 24, 2014 ... the addition of the "Global and Chinese ... their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Report 2014 is a professional and in-depth study ... industry with a focus on the Chinese situation. ...
Breaking Medicine Technology:Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 2Dental Equipment Market Current Trends, Opportunities - Global Forecast to 2019 3Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 2Local robotics teams compete - a "FIRST" at next week's MD&M Minneapolis- October 29-30th at the Minneapolis Convention Center 3Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3
... Quark siRNAs Examined Alone and in Combination ... Quark Pharmaceuticals, Inc., a,development-stage pharmaceutical company ... today announced that the,journal Cancer Research published ... target gene against non-small cell lung cancer ...
... Prophylaxis Treatment with Kogenate FS Reduces the,Risk of ... No Pre-Existing,Joint Damage, BERKELEY, Calif., Oct. 10 ... Food and Drug Administration (FDA) has,approved routine prophylaxis ... frequency of bleeding episodes and the risk of,joint ...
Cached Medicine Technology:Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5
(Date:10/25/2014)... -- A large influx of international aid is needed, ... of thousands of deaths from the widening Ebola crisis, ... Using a specially designed mathematical model, the researchers looked ... one densely populated county of hard-hit Liberia -- Montserrado ... The researchers said that if international aid isn,t delivered ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- October,s shorter, darker ... seasonal affective disorder, according to an expert. ... may feel overly tired, lack motivation and even have ... can lead to suicide, said Dr. Angelos Halaris, a ... at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... 2014 Shriners Hospitals for Children® and ... the current location of Shriners Hospitals for Children - ... from the University of Kentucky Albert B. Chandler Hospital. ... center, owned and operated by Shriners Hospitals for Children, ... children and their families well into the future. , ...
Breaking Medicine News(10 mins):Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3
... 26 John Williams,a shrimp fisherman and executive ... the House Subcommittee on Oversight and,Investigations of the ... criticized the Food and Drug Administration,s,(FDA) reliance on ... legislative actions., "On behalf of the U.S. ...
... Customers and ... Private Insurance Corporations, OAKLAND, Calif., Feb. 26 ... organized by the California,Nurses Association/National Nurses Organizing Committee that ... a,9/11 rescue worker; Donna Smith, who has recently joined ...
... Settlement on Outstanding Disputes, SPOKANE, Wash., Feb. ... Sandpoint, Idaho reached settlement on four,outstanding disputes. The ... Spokane, Washington., "This settlement is very important ... capably despite management,s refusal to negotiate a fair,contract," ...
... entertains sports world, KANSAS CITY, Mo., Feb. ... with Kansas City roots. A team of college ... premier,community for all athletes, fans, coaches and professionals., ... have a positive impact,on the entire athletic community," ...
... ARJO, Inc. announces the release,of two new lifts, and ... a unique open, twin mast design, and the SARA ... Twin has twin masts, which improve stability and weight,distribution, ... design.,All powered functions, including Powered DPS (Dynamic Positioning System),are ...
... of the Board of Directors; Daniel ... Operating Officer -, EXTON, Pa., Feb. 26 ViroPharma Incorporated,(Nasdaq: ... J.,Milano will succeed Michel de Rosen as president and chief executive,officer ... directors. Mr.,de Rosen, who has led the company as president and ...
Cached Medicine News:Health News:Testimony to Congress Denounces FDA Reliance on Self-Policing 2Health News:Michael Moore Defends 9/11 Rescue Workers and Criticizes Insurance Industry on California Nurses Association Press Call 2Health News:Nurses Convince Hospital to Return to Bargaining Table 2Health News:AthletixNation.com Launches Sports Website and Community Programs 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 2Health News:Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: